Cardinal Health's Cordis Business to Distribute Biosensors' Coronary Stent Portfolio

May 12, 2016—Cardinal Health announced that it has entered into a distribution agreement with Biosensors that enables Cordis, Cardinal Health’s interventional vascular business, to sell the coronary stent portfolio of Singapore-based Biosensors International Group, Ltd. Cordis will sell Biosensors’ coronary stents in select countries in Europe, the Middle East, Africa, Australia, and New Zealand. Biosensors’ coronary stents have not been approved by the US Food & Drug Administration and are not commercially available in the United States.

The agreement marks Cordis’ return to the drug-eluting stent (DES) market and the beginning of a long-term partnership between Cardinal Health and Biosensors to further leverage their respective distribution capabilities in select regions, noted the company.

According to Cardinal Health, Cordis will offer an expanded portfolio of products in select countries to further support the treatment of patients undergoing percutaneous coronary intervention, including devices for access, intervention, and closure.

In the next few months, Cordis will begin offering Biosensors’ coronary stent portfolio, which includes the BioFreedom polymer-free drug-coated stent, the BioMatrix NeoFlex DES, the BioMatrix Alpha cobalt chromium DES with an abluminal bioabsorbable coating, and the Chroma cobalt chromium bare-metal stent in select European countries, Australia, and New Zealand.

Over time, Cordis will begin to sell these products under the Lumeno private label in select countries, and both companies will continue to leverage their respective distribution capabilities in additional European countries, the Middle East, Africa, and other parts of the world. 

In October 2015, results from the LEADERS FREE randomized clinical trial, which was dedicated to high-bleeding-risk patients treated with 1 month of dual-antiplatelet therapy, found that Biosensors’ polymer-free BioFreedom drug-coated stent was superior to a bare-metal stent in patients undergoing PCI with respect to the primary safety and efficacy endpoints. The LEADERS FREE results were simultaneously presented at TCT 2015, the 27th annual Transcatheter Cardiovascular Therapeutics scientific symposium in San Francisco, California, and published in The New England Journal of Medicine (2015;373:2038–2047).